These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 12148000)

  • 21. Plasma product companies outmuscle small recombinant players.
    Mitchell P
    Nat Biotechnol; 2008 Oct; 26(10):1060-1. PubMed ID: 18846059
    [No Abstract]   [Full Text] [Related]  

  • 22. Plasmid integration, amplification and cytogenetics in CHO cells: questions and comments.
    Wurm FM; Petropoulos CJ
    Biologicals; 1994 Jun; 22(2):95-102. PubMed ID: 7917238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Congress works to permit 'biosimilar' drugs very soon.
    Carroll J
    Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559
    [No Abstract]   [Full Text] [Related]  

  • 24. Biotechnology. Sheep fail to produce golden fleece.
    Vogel G
    Science; 2003 Jun; 300(5628):2015-6. PubMed ID: 12829753
    [No Abstract]   [Full Text] [Related]  

  • 25. Aqueous two-phase extraction as a platform in the biomanufacturing industry: economical and environmental sustainability.
    Rosa PA; Azevedo AM; Sommerfeld S; Bäcker W; Aires-Barros MR
    Biotechnol Adv; 2011; 29(6):559-67. PubMed ID: 21501680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mammalian cell culture systems for recombinant protein production.
    Birch JR; Froud SJ
    Biologicals; 1994 Jun; 22(2):127-33. PubMed ID: 7917229
    [No Abstract]   [Full Text] [Related]  

  • 27. Merck moves into biotech.
    Kling J
    Nat Biotechnol; 2006 Jul; 24(7):730. PubMed ID: 16841041
    [No Abstract]   [Full Text] [Related]  

  • 28. Building biomanufacturing capacity--the chapter and verse.
    Kamarck ME
    Nat Biotechnol; 2006 May; 24(5):503-5. PubMed ID: 16680126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The farmyard drug store.
    Nature; 2006 Sep; 443(7107):16-7. PubMed ID: 16957702
    [No Abstract]   [Full Text] [Related]  

  • 30. Hybrid and disposable facilities for manufacturing of biopharmaceuticals: pros and cons.
    Ravisé A; Cameau E; De Abreu G; Pralong A
    Adv Biochem Eng Biotechnol; 2009; 115():185-219. PubMed ID: 19623478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of heat shock proteins (HSPs) in CHO cells for extended culture viability and improved recombinant protein production.
    Lee YY; Wong KT; Tan J; Toh PC; Mao Y; Brusic V; Yap MG
    J Biotechnol; 2009 Aug; 143(1):34-43. PubMed ID: 19527755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Veterinary vaccines in an economic and sociopolitical context. The viewpoint of the veterinary pharmaceutical industry.
    Gug M
    Dev Biol Stand; 1992; 79():31-6. PubMed ID: 1286762
    [No Abstract]   [Full Text] [Related]  

  • 33. Profit-hungry pharma sees some biotechs as ripe for the picking.
    Willyard C
    Nat Med; 2009 May; 15(5):466. PubMed ID: 19424184
    [No Abstract]   [Full Text] [Related]  

  • 34. Conversion of a CHO cell culture process from perfusion to fed-batch technology without altering product quality.
    Meuwly F; Weber U; Ziegler T; Gervais A; Mastrangeli R; Crisci C; Rossi M; Bernard A; von Stockar U; Kadouri A
    J Biotechnol; 2006 May; 123(1):106-16. PubMed ID: 16324762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Little biotech on the prairie.
    Wolfson W
    Chem Biol; 2007 Sep; 14(9):969-71. PubMed ID: 17884626
    [No Abstract]   [Full Text] [Related]  

  • 36. High-level protein expression in scalable CHO transient transfection.
    Ye J; Kober V; Tellers M; Naji Z; Salmon P; Markusen JF
    Biotechnol Bioeng; 2009 Jun; 103(3):542-51. PubMed ID: 19199356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fresh from the biologic pipeline-2009.
    Sheridan C
    Nat Biotechnol; 2010 Apr; 28(4):307-10. PubMed ID: 20379168
    [No Abstract]   [Full Text] [Related]  

  • 38. Bcl-x(L) mediates increased production of humanized monoclonal antibodies in Chinese hamster ovary cells.
    Chiang GG; Sisk WP
    Biotechnol Bioeng; 2005 Sep; 91(7):779-92. PubMed ID: 15986489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biosimilars: opportunity or cause for concern?
    Roger SD; Mikhail A
    J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weighing the outcomes.
    Russo MJ; Balekdjian D
    Nat Biotechnol; 2008 Feb; 26(2):173-82. PubMed ID: 18259169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.